Genomics plc bolsters executive leadership team with two new hires

Mark joins the company with over 16 years of medical leadership roles across several large research and development-based pharmaceutical companies, including as Chief Scientific Officer at Novartis and Associate Medical Director at GSK. Mark began his clinical career as a Medical Officer in the British Army, developing key leadership skills in a variety of challenging circumstances, and continued his medical training in the UK National Health Service specialising in anaesthesia and critical care. In 2006, he left the NHS in order to combine his medical expertise with an interest in achieving a broader impact on human health.

Nick brings over 15 years of experience in the healthcare technology space, with the past 8 years being focused solely on precision medicine. Prior to joining Genomics, Nick held various leadership roles at Helix, most recently leading strategy and business development across a number of business segments. The role included engagement with large provider networks, payors, pharmaceutical companies, life science companies and large retail pharmacies. Prior to Helix, Nick was one of the first commercial hires for GRAIL, a multi-cancer liquid biopsy company that raised over $2 billion USD before being purchased by Illumina. Earlier in his career, Nick held sales and strategy leadership roles for early stage digital health start-ups and spent 3 years with Myriad Genetics. In his role as Chief Commercial Officer, Nick will be based in the US.

Mark Toms, Chief Medical Officer, Genomics plc:
“I am delighted to join Genomics plc, particularly at such an important time. Genomics has huge potential to transform the way we approach prevention, management and treatment of common diseases, not just rare ones, and with studies such as our recent trial with the NHS on cardiovascular prevention we are bringing genomic innovation to bear in real-world clinical settings. I’m excited to lead the medical function at Genomics and to offer my knowledge and experience as we gather the evidence for the effective and safe up-take of Genomics’ technology.”

Nick DeFilippo, Chief Commercial Officer, Genomics plc:
“Being able to identify patient populations with earlier onset of common diseases will be able to improve outcomes substantially, and in time, save more lives. Creating greater access to these technologies for patients, and for healthcare providers and commissioners, is more important than ever and we will be working to achieve that across the global healthcare ecosystem, now and into the future. I am really excited to join the company and to help build the company’s presence in the US.”

Professor Sir Peter Donnelly FRS, FMedSci, Founder and Chief Executive Officer, Genomics plc:
“We are thrilled to have Mark and Nick on board, and to add their significant experience and insight to the company’s leadership team. As Genomics grows, and increases its presence commercially and clinically, their experience in the healthcare sector will be extremely valuable for us.”